Ipsen

Equities

IPN

FR0010259150

Pharmaceuticals

Real-time Euronext Paris 10:54:20 2024-05-22 am EDT 5-day change 1st Jan Change
121.5 EUR +0.16% Intraday chart for Ipsen +0.41% +12.60%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ipsen: share price up, analyst raises target CF
IPSEN : Barclays raises its target price CF
Ipsen Announces Executive Changes CI
Ipsen: new President for North America CF
IPSEN : Better-than-expected Q1; guidance unchanged Alphavalue
Transcript : Ipsen S.A., Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024
Ipsen: sales up 11% in Q1 CF
Ipsen Teams Up with Skyhawk Therapeutics on Study of RNA Modulator for Rare Neurological Diseases MT
Ipsen: collaboration agreement with Skyhawk CF
Ipsen and Skyhawk Therapeutics Announces RNA Targeting Research Collaboration in Rare Neurological Diseases CI
Ipsen: Parvus AM Europe Ltd exceeds 5% of voting rights CF
Ipsen: worldwide licensing agreement with Sutro Biopharma CF
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma MT
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan MT
IPSEN : Ipsen’s underlying fundamentals remain promising Alphavalue
Deutsche Bank Reduces Ipsen PT, Keeps Hold Rating MT
IPSEN : Deutsche Bank cuts its target CF
IPSEN : UBS reiterates its buy recommendation CF
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen MT
Ipsen: new indication approved in pancreatic cancer CF
US FDA OKs Ipsen's Metastatic Pancreatic Adenocarcinoma Treatment Regimen in Adults MT
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval DJ
Ipsen?s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA CI
Ipsen S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IPSEN : In line Q4 sales; lower-than-expected 2024 guidance Alphavalue
Chart Ipsen
More charts
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
121.3 EUR
Average target price
126.3 EUR
Spread / Average Target
+4.15%
Consensus
  1. Stock Market
  2. Equities
  3. IPN Stock
  4. News Ipsen
  5. France's Ipsen Launches Tender Offer to Purchase US Biopharmaceutical Epizyme
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW